IN8bio (INAB) investor relations material

Company overview and leadership

• Focuses on developing gamma-delta T cell therapies for autoimmune diseases and oncology, leveraging deep expertise in the field.

• Leadership team includes experts with backgrounds from LAVA Therapeutics, Adicet Bio, and GammaDelta Therapeutics.

• Recent recruitment of Dr. Oksana Poliakova to strengthen antibody and T cell engager programs.

Scientific and clinical advancements

• Developed a first-in-class T cell engager targeting CD19 and the gamma-delta T cell receptor, with a unique expansion domain to enhance efficacy.

• Demonstrated in vitro that their engager can deplete B cells more effectively and with less cytokine release than FDA-approved comparators.

• Gamma-delta T cell approach shows minimal IL-6 secretion, suggesting a lower risk of cytokine release syndrome.

• Plans to present first animal (in vivo) data in fall 2026.

Market and deal activity

• Autoimmune disease and T cell engager space is experiencing significant deal flow, with recent acquisitions and partnerships in the billions.

• Noted a shift in industry focus from cell therapy to T cell engagers due to challenges in cell therapy programs.

• Company’s unique biology and expansion domain address limitations seen in earlier gamma-delta T cell engager attempts.